Novo Nordisk terminates program on innovative insulin
Despite being proclaimed as innovative and non-traditional in 2020, Novo Nordisk has announced that development of insulin 965 has been discontinued.
by christian bundgaard, translated by daniel pedersen
Novo Nordisk has many clinical programs underway. Some make it all the way, others don’t.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk upgrades full-year guidance
For subscribers
